Moderna and Merck mRNA Vaccine Reduces Melanoma Recurrence by 49%

An mRNA vaccine developed by Moderna and Merck reduced the recurrence of melanoma by 49% over a five-year period ^[1].

This result marks a potential shift in how clinicians approach skin cancer treatment. By leveraging mRNA technology to target cancer cells, the therapy aims to prevent the return of tumors after initial treatment, potentially extending survival rates for high-risk patients.

The study, released in 2026 ^[2], focused on long-term outcomes to determine if the vaccine provided lasting protection against the disease. The data indicates that the combination therapy significantly lowers the likelihood of the cancer returning compared to standard care alone ^[1].

Melanoma is one of the most aggressive forms of skin cancer, often requiring intensive surgical and chemical interventions. The ability to cut recurrence rates by nearly half ^[1] suggests that personalized vaccines could become a primary tool in oncology. The collaboration between Moderna and Merck utilizes the same messenger RNA platform that gained global prominence during the COVID-19 pandemic.

Researchers focused on the five-year mark to ensure the vaccine's efficacy was not merely a short-term effect. The 49% reduction ^[1] provides a benchmark for future trials involving other types of solid tumors. While the study highlights a breakthrough, the companies continue to analyze the data to determine the specific patient profiles that benefit most from the treatment.